About Us
Anjarium Biosciences AG is a cell and gene therapy tools and technology company based in Switzerland and the U.S. Anjarium is capable of designing, manufacturing and supplying synthetic DNA as well as targeted non-viral vectors for the delivery of a diverse set of payloads.
We are advancing two novel technology platforms both of which are poised to disrupt current best-in-class technologies enabling improved access to genetic medicines:
pxDNA is our cell-free platform for manufacturing synthetic linear DNA. Our scalable process stands ready to replace plasmid DNA as an alternative enabling transformative biotechnology solutions for genetic medicines.
Our innovative resin technology has demonstrated significantly better recovery of enveloped viruses and exosomes compared to industry leading technologies.
Our Approach
pxDNA is our cell-free platform for manufacturing synthetic linear DNA. Our patented technology offers faster turnaround time, less impurities, higher copy number and minimal footprint requirements compared to plasmid DNA. pxDNA is well positioned to replace plasmid DNA as a key starting material for AAV, mRNA, Lentivirus and other cell and gene therapy modalities.
Our resin technology has demonstrated significantly better enveloped virus recovery compared to industry leading technologies and is poised to meaningfully reduce COGS and improve patient access to novel therapies.
Investors
Investors in Anjarium include Abingworth, Gimv, Omega Funds, Surveyor Capital (a Citadel company) and Pfizer Ventures.
Press Releases
8 DECEMBER, 2022 - Anjarium Biosciences appoints ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology Officer
18 OCTOBER, 2022 - Anjarium Biosciences appoints Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive Director
12 JULY, 2022 - Anjarium Biosciences appoints experienced industry executives
14 JUNE, 2022 - Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer
16 SEPT, 2021 - Anjarium Biosciences raises CHF 55.5M ($61M) Series A Financing to develop next-generation non-viral gene therapies
Careers
Join us in transforming how life-changing genetic medicines are created
Anjarium is assembling a world-class global team to accelerate access to revolutionary cell and gene therapies with next generation tools and technology platforms.